WRBYWarby Parker Inc.
Is the price fair?
Priced for +33% a year vs +13% a year delivered. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~33% a year FCF growth. The price demands more than its three-year revenue growth of 13% a year, priced for acceleration.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What WRBY's price assumes
Warby Parker Inc. trades at 361× earnings against 39.6× for the median Medical Instruments & Supplies name, more expensive than its own group.
Trailing P/E · Medical Instruments & Supplies median 39.6 · 9.12× the median: the market pays up for this one
- Price / sales
- 3.87
Price / sales · today's price, fiscal year to Dec 31, 2025
- Free cash flow yield
- 0.64%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
- Growth the price implies
- +33%
Growth the price implies · The price pays for +33% free cash flow growth a year for a decade; revenue has grown +13% a year over the last three.
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 9.18
- EV / EBIToperating margin 0.17%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 3.54
- Healthcare median P/E509 names
- 26.2
- Medical Instruments & Supplies median P/E33 names
- 39.6
- Free cash flow, trailing twelve months
- $22M
- Market capitalisation
- $3.37B
- 3-year revenue growth
- +13%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #19 of 21 by RyuScore